Results 1 to 10 of about 7,789 (204)

Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports [PDF]

Frontiers in Immunology
Upadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis.
Rui Mo, Shuxia Yu, Hongwei Xu, Jinghua Hao   +3 more
doaj   +2 more sources

REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY) [PDF]

Arquivos de Gastroenterologia
Background: Extraintestinal manifestations (EIMs) significantly impact patients with inflammatory bowel disease (IBD). Janus kinase inhibitors (JAKi) are emerging as a potential treatment.
Viviana PARRA-IZQUIERDO, Oscar ARDILA, Juan Ricardo MÁRQUEZ, Javier RIVEROS, Álvaro Andrés GÓMEZ-VENEGAS, Carlos Andrés MEDRANO-ALMANZA, Manuel BALLESTEROS, Jonathan BARRETO-PÉREZ, Juan Sebastian FRIAS-ORDOÑEZ   +8 more
doaj   +2 more sources

Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib. [PDF]

Dermatol Ther (Heidelb)
Gwag HE, Park M, Park SY, Hong N, Heo SJ, Jung HJ, Park MY, Choi YS, Ahn J.   +8 more
europepmc   +3 more sources

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease [PDF]

New England Journal of Medicine, 2023
Edward V. Loftus, Julián Panés, Ana P. Lacerda, Laurent Peyrin‐Biroulet, Geert D’Haens, Remo Panaccione, Walter Reinisch, Édouard Louis, Minhu Chen, Hiroshi Nakase, Jakob Begun, Brigid S. Boland, Charles D. Phillips, Mohamed‐Eslam F. Mohamed, Jianzhong Liu, Ziqian Geng, Feng Tian, Elena Dubcenco, Jean‐Frédéric Colombel   +18 more
exaly   +2 more sources

Use of Janus Kinase Inhibitor Upadacitinib in Microscopic Colitis. [PDF]

ACG Case Rep J
Mumm B, Stein DJ.
europepmc   +2 more sources

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Lancet, The, 2019
Atul Deodhar, Mrcp, Filip E Van Den Bosch, Walter P Maksymowych   +2 more
exaly   +3 more sources

Upadacitinib for the Treatment of Cutaneous Crohn's Disease Presenting as Lymphangioma Circumscriptum. [PDF]

ACG Case Rep J
Gerstein B, Lau WC, Bitterman A, Adalsteinsson JA, Gottlieb Z, Kassenoff R, Cices A.   +6 more
europepmc   +2 more sources

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Heliyon, 2023
Background: The sparsity of head-to-head trials for medications used as in atopic dermatitis (AD) treatment makes therapy options difficult. Objective: To better compare the efficacy and safety of abrocitinib and upadacitinib with dupilumab in patients ...
Qin Gao, Yanxia Zhao, Junling Zhang
doaj   +1 more source

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study

Dermatology and Therapy, 2023
Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib.
Nobukazu Hayashi, Masanori Ikeda, John Liu, Eliza Raymundo, Yingyi Liu, Takuya Sasaki, Kenshi Yamasaki   +6 more
doaj   +1 more source

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

RMD Open, 2022
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14
Désirée van der Heijde, Filip van den Bosch, Atul Deodhar, Joachim Sieper, Bernard Combe, Walter P Maksymowych, In-Ho Song, Tae-Hwan Kim, Mitsumasa Kishimoto, Yuanyuan Duan, Yunxia Sui, Andrew J Östör, Peter K Wung   +12 more
doaj   +1 more source